5 research outputs found
WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response
Genomic instability is a hallmark of cancer. The WW domaincontaining
oxidoreductase (WWOX) is a tumor suppressor spanning
the common chromosomal fragile site FRA16D. Here, we report a
direct role ofWWOXin DNA damage response (DDR) and DNA repair.
We show that Wwox deficiency results in reduced activation of the
ataxia telangiectasia-mutated (ATM) checkpoint kinase, inefficient
induction and maintenance of γ-H2AX foci, and impaired DNA repair.
Mechanistically, we show that, upon DNA damage, WWOX accumulates
in the cell nucleus, where it interacts with ATM and enhances its
activation. Nuclear accumulation of WWOX is regulated by its K63-
linked ubiquitination at lysine residue 274, which is mediated by the
E3 ubiquitin ligase ITCH. These findings identify a novel role for the
tumor suppressor WWOX and show that loss of WWOX expression
may drive genomic instabilityWe thank Dr. Eugenio Gaudio and Dr. Sonja Matt for
technical help, Dr. Yossi Shiloh for the ataxia telangiectasia-mutated inhibitor,
and Dr. Kay Huebner for the rabbit polyclonal WW domaincontaining
oxidoreductase antibody. This study was supported by a German
Israeli Foundation Joint Grant (to T.G.H. and R.I.A.), Israeli Cancer Research
Funds (to Z.S. and R.I.A.), Deutsche Forschungsgemeinschaft Grant SFB1036
(to T.G.H.), and the Deutsche Krebshilfe (T.G.H.)
Recommended from our members
Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses
Host immunity provides wide spectrum protection that serves to eradicate pathogens and cancer cells, while maintaining self-tolerance and immunological homeostasis. Ligation of the T cell receptor (TCR) by antigen activates signaling pathways that coordinately induce aerobic glycolysis, mitochondrial activity, anabolic metabolism, and T effector cell differentiation. Activation of PI3K, Akt, and mTOR triggers the switch to anabolic metabolism by inducing transcription factors such as Myc and HIF1, and the glucose transporter Glut1, which is pivotal for the increase of glucose uptake after T cell activation. Activation of MAPK signaling is required for glucose and glutamine utilization, whereas activation of AMPK is critical for energy balance and metabolic fitness of T effector and memory cells. Coinhibitory receptors target TCR-proximal signaling and generation of second messengers. Imbalanced activation of such signaling pathways leads to diminished rates of aerobic glycolysis and impaired mitochondrial function resulting in defective anabolic metabolism and altered T cell differentiation. The coinhibitory receptors mediate distinct and synergistic effects on the activation of signaling pathways thereby modifying metabolic programs of activated T cells and resulting in altered immune functions. Understanding and therapeutic targeting of metabolic programs impacted by coinhibitory receptors might have significant clinical implications for the treatment of chronic infections, cancer, and autoimmune diseases
Recommended from our members
Clinical significance of T cell metabolic reprogramming in cancer
Conversion of normal cells to cancer is accompanied with changes in their metabolism. During this conversion, cell metabolism undergoes a shift from oxidative phosphorylation to aerobic glycolysis, also known as Warburg effect, which is a hallmark for cancer cell metabolism. In cancer cells, glycolysis functions in parallel with the TCA cycle and other metabolic pathways to enhance biosynthetic processes and thus support proliferation and growth. Similar metabolic features are observed in T cells during activation but, in contrast to cancer, metabolic transitions in T cells are part of a physiological process. Currently, there is intense interest in understanding the cause and effect relationship between metabolic reprogramming and T cell differentiation. After the recent success of cancer immunotherapy, the crosstalk between immune system and cancer has come to the forefront of clinical and basic research. One of the key goals is to delineate how metabolic alterations of cancer influence metabolism-regulated function and differentiation of tumor resident T cells and how such effects might be altered by immunotherapy. Here, we review the unique metabolic features of cancer, the implications of cancer metabolism on T cell metabolic reprogramming during antigen encounters, and the translational prospective of harnessing metabolism in cancer and T cells for cancer therapy
Evaluation of Tumor-Associated Antigen MUC1 Expression with the MACSima (TM) High-Content Imaging Platform
MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors
Many critical advances in research utilize techniques that combine high-resolution with high-content characterization at the single cell level. We introduce the MICS (MACSima Imaging Cyclic Staining) technology, which enables the immunofluorescent imaging of hundreds of protein targets across a single specimen at subcellular resolution. MICS is based on cycles of staining, imaging, and erasure, using photobleaching of fluorescent labels of recombinant antibodies (REAfinity Antibodies), or release of antibodies (REAlease Antibodies) or their labels (REAdye_lease Antibodies). Multimarker analysis can identify potential targets for immune therapy against solid tumors. With MICS we analysed human glioblastoma, ovarian and pancreatic carcinoma, and 16 healthy tissues, identifying the pair EPCAM/THY1 as a potential target for chimeric antigen receptor (CAR) T cell therapy for ovarian carcinoma. Using an Adapter CAR T cell approach, we show selective killing of cells only if both markers are expressed. MICS represents a new high-content microscopy methodology widely applicable for personalized medicine